The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Open accessAbstract
Topoisomerase poisons are chemotherapeutic agents that are used extensively for treating human malignancies. These drugs can be highly effective, yet tumors are frequently refractory to treatment or become resistant upon tumor relapse. Using a pool-based RNAi screening approach and a well characterized mouse model of lymphoma, we explored the genetic basis for heterogeneous responses to topoisomerase poisons in vitro and in vivo . These experiments identified Top2A expression levels as major determinants of response to the topoisomerase 2 poison doxorubicin and showed that suppression of Top2A produces resistance to doxorubicin in vitro and in vivo . Analogously, using a targeted RNAi approach, we demonstrated that suppression of Top1 produces resistance to the topoisomerase 1 poison camptothecin yet hypersensitizes cancer cells to doxorubicin. Importantly, lymphomas relapsing after treatment display spontaneous changes in topoisomerase levels as predicted by in vitro gene knockdown studies. These results highlight the utility of pooled shRNA screens for identifying genetic determinants of chemotherapy response and suggest strategies for improving the effectiveness of topoisomerase poisons in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Self-citationp53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationCamptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Self-citationThe INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Cited by
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Doxorubicin, DNA torsion, and chromatin dynamics
Yang, F., Teves, S. S., Kemp, C. J., & Henikoff, S. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.002 · Cited by 695
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 466
DNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428
Self-citationActive targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Huang, B., Abraham, W. D., Zheng, Y., Bustamante López, S. C., Luo, S. S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 312
The combined status of ATM and p53 link tumor development with therapeutic response
Jiang, H., Reinhardt, H. C., Bartkova, J., Tommiska, J., Blomqvist, C., Nevanlinna, H., Bartek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 304
Self-citationAutophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
Koleini, N., & Kardami, E. (2017) · Oncotarget · doi:10.18632/oncotarget.16944 · Cited by 301
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
Self-citationDauch, D., Rudalska, R., Cossa, G., Nault, J.-C., Kang, T.-W., Wuestefeld, T., Hohmeyer, A., Imbeaud, S., Yevsa, T., Hoenicke, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4107 · Cited by 273
Self-citationTrapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190
Self-citationBruno, P. M., Lu, M., Dennis, K. A., Inam, H., Moore, C. J., Sheehe, J., Elledge, S. J., Hemann, M. T., & Pritchard, J. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921649117 · Cited by 175
Self-citationCRISPR Approaches to Small Molecule Target Identification
Jost, M., & Weissman, J. S. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00965 · Cited by 88
Ablation of the kinase NDR1 predisposes mice to the development of T cell lymphoma.
Cornils, H., Stegert, M. R., Hergovich, A., Hynx, D., Schmitz, D., Dirnhofer, S., & Hemmings, B. A. (2010) · Science Signaling · doi:10.1126/scisignal.2000681 · Cited by 72
Sullivan, R., & Graham, C. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1090 · Cited by 65
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Metadata
- Authors
- Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-07
- Volume
- 105
- Issue
- 26
- Pages
- 9053-9058
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2114800396
- Cited by
- 300
- References
- 38
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.